Our Take
India's move is tactical, not visionary—it targets the 40 HS codes that drain 85% of the import budget, which means policy support will concentrate firepower rather than scatter it.
Why it matters
Medical device imports rose 17% year-over-year to ₹89,000 crore, signaling both dependency and opportunity. Manufacturers and suppliers embedded in import chains should expect tariff and procurement policy shifts within months.
Do this week
Supply chain leads: audit your top 10 suppliers for each device category on the government's shortlist (MRI, pacemakers, CGM, ultrasound, X-ray, ICU beds, diagnostics) before Q3 2026 so you can identify domestication risks and contract renegotiation windows.
India's medical device import problem is becoming a policy priority
The Indian government is in active consultation with the Department for Promotion of Industry and Internal Trade (DPIIT) to identify 8–10 high-value medical devices for accelerated local production. The Centre has reviewed import data and is building an internal priority list, with targeted support measures under review including tariff adjustments, component indigenisation mandates, public procurement incentives, R&D grants, and subsidies.
Devices under consideration include MRI systems and components, continuous glucose monitoring (CGM) systems, high-end ultrasound probes and consoles, X-ray tubes and imaging detectors, ICU beds, high-throughput diagnostic analysers, and pacemakers.
The context is stark. India imports 6,000 medical devices across 160 product categories (HS codes). Of those, 40 categories with imports exceeding ₹500 crore each account for ₹77,000 crore—nearly 85% of the total import bill (per industry body AiMeD). The top 19 products alone represent ₹26,000 crore, or 30% of all imports. Medical device imports rose 17% year-over-year to ₹89,000 crore in the most recent reporting period, up from ₹76,000 crore (per AiMeD). India imports roughly $8 billion in medical devices annually while exporting $4 billion.
Industry executives are also expecting an extension of the existing production-linked incentive (PLI) scheme or a new PLI 2.0 programme for the medtech sector. Rajiv Nath, forum coordinator at AiMeD, described the move as "timely."
The 40-code concentration makes this actionable
Policy support typically dilutes when aimed at an entire sector. This initiative is different: 85% of India's medical device import bill flows through just 40 product codes. That concentration means government support (tariffs, subsidies, procurement preferences) can move the needle on actual domestic capacity rather than generate symbolic announcements.
The shortlist discipline also signals realistic priorities. MRI systems, pacemakers, and advanced diagnostics are complex, import-dependent, and high-value—precisely where local production capability either exists or can be built with targeted R&D and component supply chains. Smaller, lower-complexity devices are not on the list, which suggests the government understands its leverage.
Timing matters too. Import dependency in medical devices intersects healthcare security (supply chain resilience), currency outflow (hard forex), and industrial policy (job creation, tech capability). All three have political weight, which improves the odds that announced measures will be legislated rather than shelved.
What to do this week
If you supply components or finished goods into any of these categories—imaging systems, glucose monitoring, pacemakers, X-ray equipment, diagnostics analysers—treat this as a contract renegotiation signal.
Importers and distributors should map their supply chains against the 40 high-volume HS codes immediately. Tariff changes, local content requirements, or procurement preferences could reshape your margin structure or competitive position within 6–12 months. Engage with industry bodies like AiMeD to track the policy detail as it emerges.
Original equipment manufacturers (OEMs) with existing India operations or greenfield ambitions should prepare for public procurement incentives. State tenders for hospital equipment and diagnostics often follow federal industrial policy signals, and early compliance with local production goals unlocks preferred-vendor status.